Reuters logo
BRIEF-Living Cell Technologies receives approval to commence treating patients in clinical trial of ntcell for Parkinson's disease
February 8, 2017 / 12:18 AM / in 8 months

BRIEF-Living Cell Technologies receives approval to commence treating patients in clinical trial of ntcell for Parkinson's disease

Feb 8 (Reuters) - Living Cell Technologies Ltd-

* Living cell technologies -received approval to commence treating six patients in group 3 of phase iib clinical trial of ntcell for parkinson’s disease Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below